Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1158780/000121390023076079/f10k2023_pluriinc.htm
July 2023
July 2023
April 2023
April 2023
February 2023
January 2023
December 2022
December 2022
October 2022
September 2022
Document And Entity Information - USD ($) | 12 Months Ended | ||
---|---|---|---|
Jun. 30, 2023 | Sep. 08, 2023 | Dec. 31, 2022 | |
Document Information Line Items | |||
Entity Registrant Name | PLURI INC. | ||
Trading Symbol | PLUR | ||
Document Type | 10-K | ||
Current Fiscal Year End Date | --06-30 | ||
Entity Common Stock, Shares Outstanding | 41,351,870 | ||
Entity Public Float | $ 34,413,220 | ||
Amendment Flag | false | ||
Entity Central Index Key | 0001158780 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Well-known Seasoned Issuer | No | ||
Document Period End Date | Jun. 30, 2023 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity File Number | 001-31392 | ||
Entity Incorporation, State or Country Code | NV | ||
Entity Tax Identification Number | 98-0351734 | ||
Entity Address, Address Line One | MATAM Advanced Technology Park | ||
Entity Address, Address Line Two | Building No. 5 | ||
Entity Address, City or Town | Haifa | ||
Entity Address, Country | IL | ||
Entity Address, Postal Zip Code | 3508409 | ||
City Area Code | 972 | ||
Local Phone Number | 74-7108600 | ||
Title of 12(b) Security | Common Shares, par value $0.00001 | ||
Security Exchange Name | NASDAQ | ||
Entity Interactive Data Current | Yes | ||
Document Financial Statement Error Correction [Flag] | false | ||
Auditor Firm ID | 1309 | ||
Auditor Name | Kesselman & Kesselman Certified Public Accountants (lsr.) | ||
Auditor Location | Haifa, Israel |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1158780/000121390023076079/f10k2023_pluriinc.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Pluri Inc..
Pluri Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Rating
Learn More![]()
Pursuant to the securities purchase agreements executed with the purchasers, we agreed to hold a meeting of shareholders within 200 days of the execution of the securities purchase agreements for the purpose of increasing our authorized shares.
The increase in weighted average common shares outstanding reflects the issuance of additional shares pursuant to a private placement offering we conducted in December 2022, or the December 2022 Private Placement, and the issuance of additional shares upon the vesting of RSUs issued to directors, employees and consultants.
The decrease is mainly attributed to: (1) a decrease in clinical studies expenses following the completion of our CLI and ARDS associated with COVID-19 studies and the end of enrollment of our muscle regeneration following hip fracture study in November 2021, (2) a decrease in material purchases in accordance with our manufacturing needs and plans, (3) a decrease in salaries and related expenses as part of our efficiency cost-reduction plan , specifically a reduction of 22 research and development, or R&D, employees in Pluri Biotech Ltd. (108 on June 30, 2023, compared to 130 on June 30, 2022), (4) a decrease in share-based compensation expenses and (5) higher participation by the European Union with respect to the Horizon 2020 grants, which relate to our CLI and muscle regeneration following hip fracture studies.
In addition, the purchasers in the December 2022 Private Placement agreed to execute proxies permitting our CEO and CFO to vote the securities purchased in the December 2022 Private Placement in favor of any shareholder vote relating to a future increase of our authorized shares.
Research and development, net (costs less participation and grants by the IIA, Horizon 2020, Horizon Europe and other parties) decreased by 35% from $24,377,000 for the year ended June 30, 2022, to $15,745,000 for the year ended June 30, 2023.
Between December 13, 2022, and...Read more
On April 27, 2023, our...Read more
General and administrative expenses decreased...Read more
Upon entering into the ATM...Read more
We are utilizing our technology...Read more
We are continually looking for...Read more
Our cash equivalents and restricted...Read more
On December 13, 2022, we...Read more
On December 14, 2022, we...Read more
On December 15, 2022, we...Read more
On December 19, 2022, we...Read more
On December 27, 2022, we...Read more
The value of the portion...Read more
Through June 30, 2023, we...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Pluri Inc. provided additional information to their SEC Filing as exhibits
Ticker: PLUR
CIK: 1158780
Form Type: 10-K Annual Report
Accession Number: 0001213900-23-076079
Submitted to the SEC: Tue Sep 12 2023 4:01:06 PM EST
Accepted by the SEC: Tue Sep 12 2023
Period: Friday, June 30, 2023
Industry: Biological Products No Disgnostic Substances